J&J to Acquire Firefly, Maker of ‘Degrader’ Antibody Drugs, for $1B

J&J spends $1 billion to enter KRAS race for cancer treatments

Johnson & Johnson's acquisition of the startup, Firefly Bio, follows the release of field-changing data from Revolution Medicines.

Johnson & Johnson to buy Firefly Bio for $1B in cash (JNJ:NYSE)

Johnson & Johnson to acquire Firefly Bio for $1B, boosting its oncology pipeline with Firelink DAC targeting KRAS-driven solid tumors.

J&J to acquire Firefly, maker of ‘degrader’ antibody drugs, for $1B

The buyout hands J&J a technology that merges elements of two popular drugmaking methods: protein degraders and antibody-drug conjugates.

Johnson & Johnson Acquires Firefly Bio for $1 Billion to Advance KRAS Cancer Therapies

J&J to Acquire Firefly Bio for $1 Billion, Strengthening Next-Generation KRAS Cancer Pipeline New Brunswick, NJ: Johnson & Johnson has announced a definitive agreement to acquire biotechnology company Firefly Bio, Inc. for $1 billion in cash, expanding its oncology pipeline with a novel antibody-based protein degradation platform designed to target some of the most difficult-to-treat […] The post Johnson & Johnson Acquires Firefly Bio for $1 Bil…

J&J to acquire Firefly Bio for $1bn to enhance oncology pipeline

The deal centres on enhancing targeted treatments for solid tumours driven by KRAS mutations, which are considered especially challenging to treat. The companies stated that the Firelink DAC The post J&J to acquire Firefly Bio for $1bn to enhance oncology pipeline appeared first on Pharmaceutical Business review.

J&J makes $1B move for Firefly Bio, Carolyn Bertozzi's twist on ADCs in KRAS field

Johnson & Johnson is making another early-stage oncology deal, dishing out $1 billion in cash to acquire Firefly Bio, a preclinical startup working on degrader antibody conjugates. J&J now joins the 2026 pharma dealmaking frenzy ...